Treatment Strategies for Specific p53 Mutations

Mr. Prathmesh Sudhir Gogate

Saraswati Institute of Pharmacy Kurtadi, Waranga, Hadgaon Rd, Kurtadi, Maharashtra 431701

Abstract

TP53 is a tumor suppressor gene that is mutated in some 50-60 percent of human cancers and is quite different in distribution among cancer types and histological subtypes. Recent development of molecular profiling and treatment development has shown a great deal of functional heterogeneity among various p53 mutations, and not all cancers with p53-mutations can be treated in a uniform manner. This is a review of existing evidence on mutation-specific biology of p53 and emerging treatments. We comment on the hotspot mutations (R175H, R248W, R273H) and their unique oncogenic effects, mechanisms of the loss-of-function and gain-of-function effects and the mutation-specific sensitivity to therapies. The modern therapeutic approaches involve p53-reactivating compounds (APR-246, COTI-2, eprenetapopt), MDM2 inhibitors, gene therapy (Gendicine), calcium-signaling, and immunotherapy combinations. It is important to note that current findings indicate that some mutation of p53 (e.g., R273H) can render tumors vulnerable to immune checkpoint inhibitors using the genomic instability mechanisms, which can be used to open new therapeutic opportunities. The review highlights the paramount role of thorough TP53 mutation analysis in the stratification of the treatment and the combination therapy strategies as the existing method of the greatest therapeutic efficacy enhancement. Our conclusion is that p53-directed therapy is a paradigm shift of one size fits all chemotherapy to precision medicine, which has serious consequences to enhance the outcomes of patients with p53-mutant malignancies.

Keywords: p53 mutations, medicine, p53-directed therapy, precision oncology, mutation-specific treatment.

1. Introduction

1.1 The p53 Tumor Suppressor: Guardian of the Genome

TP53 gene that codes p53 protein is one of the most studied tumor suppressor genes in cancer biology[1][2]. As it is often mentioned, p53 is the so-called guardian of the genome and it plays a key role in keeping the integrity of cells steady through several mechanisms[2][3]. Wild-type p53 is a transcription factor that controls the various cellular functions such as cell cycle arrest, apoptosis, DNA damage repair, cellular senescence, metabolic adaption and immune surveillance[1][3][4].

In a healthy state, p53 protein is kept at a low concentration due to ubiquitination by MDM2 (mouse double minute 2) which causes p53 to be degraded by the proteasomes[1][3]. In response to cellular stress, p53 becomes stabilized and activated upon MDM2 inhibition through DNA damage, hypoxia, nutrient starvation, or oncogenic activation, etc. [1]. The binding of stabilized p53 as a homotetramer to promoter sequences of about 500 target genes results in transcription of these sequences leading to the expression of many different cellular responses[1][3].

1.2 The TP53 Mutation Landscape in Cancer

About half of all human cancers have TP53 mutations, which are found in up to 80 percent of some types of cancerous cells [2] [5]. Pan-cancer studies indicate that there is a significant difference in the frequency of mutation across different tissues: lung cancer (70 percent), gastric cancer (60 percent), breast cancer (20-80 percent, depending on subtype), oesophageal cancer (60 percent), colorectal cancer (50-60 percent), and hepatocellular carcinoma (30-50 percent) [2][5].

TP53 mutations cover the spectrum that includes missense changes (~75 percent), frameshift or other deletion or insertion mutations (~9 percent) and nonsense/stop mutations (~7 percent) and silent mutations (~5 percent) [2][5]. More than 2,000 different TP53 mutations have been reported, approximately three-quarters of them at six active amino-acid residues on the DNA binding domain: R175, G245, R248, R249, R273, and R282 [1][2][5].

1.3 Clinical Significance and Treatment Implications

TP53 mutations are closely linked with low survival rates, chemotherapy resistance and decreased overall survival in various types of cancer[1][2][4][5]. Nevertheless, new findings are revealing that there is a big functional heterogeneity among various p53 mutations with certain mutations having different molecular pathways, oncogenicity and therapeutic susceptibility[5][6][7][8].

2. Functional Heterogeneity of p53 Mutations: Beyond Loss-of-Function

2.1 Mechanisms of p53 Inactivation

TP53 mutations stimulate cancer in three main ways:

Loss-of-Function (LOF) Effects: LOF mutations inhibit the functions of p53 in the cell. These are usually frameshift insertions/deletions and nonsense mutations that result in truncated inactive p53 proteins[2][5].

Dominant-Negative Effects (DNE): In the initial tumorigenesis, cells accumulate wild-type and mutant alleles of p53 at the same time. The mutant protein disrupts the wild-type p53 functioning by forming heterotetrameric complexes[5][6].

Gain-of-Function (GOF) Effects: There is the acquisition of new oncogenic functions by mutant p53 proteins that does not depend on the loss of wild-type p53[5][6][7].

GOF effects entail mutant p53 binding regulation to transcription factors which are not regulated by wild-type p53 which alter gene expression programs that foster cancer cell survival, proliferation, invasion, and drug resistance[5][6][7][8].



2.2 Hotspot Mutations: Distinct Functional Profiles

R175H Mutation: R175H mutation is most often identified as a missense mutation of the p53 gene in all human malignancies although it has the greatest prevalence in cerebral and esophageal neoplasma[1][2][8]. Recent studies have shown that unequal amino-acid replacement at the arginine 175 site i.e. R175H, R175G have different molecular mechanisms [8]. This fact demonstrates the urgent need of mutation-specific therapeutic interventions, even in the case of the same-residue substitutions[8].

R273H Mutation: R273H is another mutation that is a frequently observed hot spot mutation. New evidence shows that R273H variants create a novel therapeutic opportunity through immune activation using the aid of genomic instability[8][9]. The mechanistic studies prove that the mutant form of R273H of p53 generates excessive and abnormal UDNA replication thus contributing to genomic instability by developing micronuclei[9]. The instability then activates the cGASSTING innate immune pathway[9].

R248W and Other Residue 248 Mutations: R248W mutations present in pancreatic ductal adenocarcinoma cell lines amplify STAT3 signaling that increases cell migration and invasion of the cancer cells[6][8].

2.3 Mutation Type-Specific Cellular Phenotypes

Frameshift and Stop Mutations: These mutations lead to loss-of-function phenotypes, which cause the deletion of transcriptional regulatory activity of p53[5][6][7]. They are also linked to the reduced store-based calcium entry (SOCE) of triple negative breast cancer[5][7].

Missense Mutations whose Functional Profiles are Variable: The heterogeneous functional consequences of missense variants. Some mutations including R273H can still maintain residual wild-type activity or have new gain-of-function functions, but others are much closer to loss-of-function phenotypes[5][6][8].

3. Molecular Mechanisms of p53 Dysfunction and Cancer Progression

3.1 Transcriptional and Non-Transcriptional Functions of p53

Wild-type p53 protein regulates both transcriptional and non-transcriptional oncogenic phenotypes[1][3][4]. This transcriptional activity can be described as its role as a DNA-binding transcriptional factor that activates pro-apoptotic gene expression including PUMA, NOXA, BAX, and PARP, cell-cycle arresting genes including p21 and CDKN1A, DNA-repair genes, metabolic controllers and immune system members[1][3][4][7].

Besides, non-transcriptional processes of p53 include direct translocation of p53 to mitochondria and its binding to anti-apoptotic Bcl-2 family members, thus contributing to outer membrane permeabilization of mitochondria and apoptosis induction[1][3][4].

3.2 The p53-MDM2 Regulatory Axis and Therapeutic Opportunity

In wild-type cells, MDM2 interacts with p53 and causes it to be degraded by the proteasome and keeps the p53 levels low[1][3][4]. This interaction is a significant therapeutic focus since its interference can restore the function of p53 in tumors with wild-type TP53[1][3][4].

Nonetheless, in tumors with TP53 mutations, mutant protein accumulation tends to take place using diminished MDM2 binding and must be taken care of using alternative treatment modalities[2][5][6].



3.3 The Calcium Signaling Axis: A Novel p53-Regulated Pathway

Recent studies indicate that p53 plays a pivotal role in the intracellular calcium homeostasis regulation, especially the store-operated calcium entry (SOCE)[5][7]. p53 activates the expression of CACNA1D and facilitates the calcium storage in endoplasmic reticulum stores in wild-type p53 cells[5][7].

CACNA1D is downregulated in frameshift and stop TP53 mutant cells, which lowers the basal calcium levels and inhibits SOCE activity[5][7]. This pathway is one of the p53-mediated tumor suppresses and a possible locus of therapeutic action[5][7].

4. Contemporary Therapeutic Strategies for p53-Mutant Cancers

4.1 p53-Reactivating Compounds: Small Molecule Therapeutics

APR-246 (Eprenetapopt): APR-246 is the original p53-reactivating compounds to enter the extensive clinical development[2][10]. The thiosemicarbazone derivative reacts with cysteine residues of the p53 DNA-binding domain stabilizes the wild-type conformation and reinstates transcriptional activity[2][10][11]. The Phase I/ II clinical trials showed safety, tolerability, and biological activity in patients having p53-mutant hematology malignancies[10][11]. APR-246 was combined with carboplatin and pegylated doxorubicin in a phase II trial in high-grade serous recurrence ovarian cancer, which is sensitive to platinum, and 3 complete responses, 10 partial responses, and 8 stable disease were observed in 21 evaluable patients[2][10][11].

COTI-2 (Third-Generation Thiosemicarbazone): COTI-2 is a stronger third-generation generation of thiosemicarbazones p53 reactivator, and it is more potent than APR-246[5][11][12]. COTI-2 works by binding to mutant p53 that is misfolded and causes conformational change to restore tumor suppressor activity[5][11][12]. In recent literature, COTI-2 has been found to reestablish CACNA1D expression and SOCE activity in frameshift and stop TP53 mutant cells to increase their sensitivity to apoptosis by restoring calcium-signaling[5][7]. COTI-2 used with thapsigargin synergistically induces apoptosis in the p53-mutant TNBC cells[5][7].

4.2 MDM2 Inhibitors: Reactivating Wild-Type p53

One of the significant drug classes is MDM2 inhibitors, which specifically inhibit the MDM2-p53 interaction and the drug class has been particularly useful in tumors with wild-type TP53[1][3][4][10][11]. These compounds inhibit MDM2-p53 binding, which causes p53 ubiquitination and degradation, and stabilize and reactivate p53[1][3][4][10]. Nutlin Family and Small Molecules Related Nutlin-3a and other analogues are the first generation of MDM2 inhibitors. The efficacy in wild-type p53 tumors is demonstrated in preclinical studies[10][11].

PROTAC-Based MDM2 Degraders: New PROTAC (proteolysis targeting chimera) technologies have produced MDM2 degraders that mediate their activity at nanomolar concentrations without toxicity[10].Clinical Applications in post-operative and advanced biliary tract cancer, regimens with MDM2 inhibitors increased the cycle of responding patients two times higher as the standard chemotherapy[10]. In acute myeloid leukemia, the combination therapy of MDM2 inhibitor increased remission[10].



4.3 Gene Therapy: Recombinant Adenoviral p53

The first-in-human cancer gene therapy drug approved to be clinically used is recombinant adenoviral p53 (rAd-p53) which is marketed as Gendicine[2][10][11]. Mechanism and Clinical Applications: Gendicine represents a modified type 5 adenovirus which has been modified to express wild-type p53 under constitutive regulation[2][10][11]. These are intra-tumoral injection, intra-arterial infusion, perfusion and systemic intravenous routes of administration[2][10][11][13]. Clinical Efficacy: Clinical evidence shows a high level of efficacy[2][10][11][13]: Head and Neck Cancers: Complete response 30% partial response 54%

stable disease 12.5% yield >84% disease control rates, Gynecological Cancers: better progress free and overall survival with platinum-based chemotherapy. Lung Cancers: Response to combinatorial therapy with chemotherapy or radiotherapy. Safety Profile: Gendicine is associated with a good safety profile with adverse events that can be managed[2][10][11].

4.4 Calcium-Signaling Modulation: An Emerging Therapeutic Avenue

CACNA1D Restoration and SOCE Increase: p53-reactivating compounds recover CACNA1D expression and SOCE increase in p53-mutant frameshift and stop mutation cells[5][7]. Combination with SERCA Inhibitors: SERCA inhibitors (Thapsigargin) induce synergistic apoptosis when p53-reactivating compounds are used together with SERCA inhibitors in p53-mutant TNBC cells[5][7].

5. Immunotherapy as a Mutation-Specific Treatment Strategy

5.1 p53 Mutations and Immune Checkpoint Inhibitor Sensitivity

Recent findings indicate that certain p53 mutations confer changes in tumor immunogenicity and immune checkpoint inhibitor (ICI) sensitivity[6][8][9]. Instead of inducing homozygous immunological tolerance, some p53 mutations establish inflammatory tumor micro-ecosystems that are conducive to immune mediated assault[6][8][9].

5.2 The R273H Mutation as an Immunotherapy Biomarker

Recently, it has been shown that the ICI sensitivity in tumors containing the p53 R273H contact mutation is sensitised by genomic instability-driven immune activation[9]. Over-replication of DNA: R273H mutant p53 enhances the abnormal DNA replication surpassing the usual cell cycle prerequisites[9]. cGAS-STING Pathway Stimulation: Micronuclei contain cytosolic double-stranded DNA which stimulates the cGAS-STING innate immune pathway[9]. Improved ICI Response: Model Preclinical breast cancers bearing R273H have improved CD8+ T cell infiltration and immune killing in response to anti-PD-1 checkpoint inhibitors[9].

5.3 Clinical Implications and Patient Stratification

These findings indicate future immunotherapy solutions in which patients with R273H mutations are considered to be the treatment options of immune checkpoint blockers on the basis of anticipated high responsiveness[9].

5.4 Combination Immunotherapy-Chemotherapy Approaches

New approaches include the use of ICI in combination with drugs against DNA replication machinery (e.g. ATR inhibitors, PARP inhibitors) to further boost immune responses in p53-mutant tumors[9][10].

6. Synthetic Lethality and DNA Repair Targeting

6.1 Synthetic Lethal Vulnerabilities in p53-Mutant Cancers

Synthetic lethality methods determine gene pairs in which the inhibition of one gene is fatal, but only when the other gene is also inhibited[10][11].

6.2 ATR Inhibitors and DNA Replication Checkpoint Control

One of the most important synthetic lethal approaches in p53-mutant tumors is ATR (ataxia telangiectasia and Rad3-related) kinase inhibitors. G1/S checkpoint in p53-mutant cells is absent, and therefore, cells in this case rely on the G2/M ATR-CHK1 checkpoint to survive after DNA damage[10][11].

6.2 ATR Inhibitors and DNA Replication Checkpoint Control

One of the most important synthetic lethal approaches in p53-mutant tumors is ATR (ataxia telangiectasia and Rad3-related) kinase inhibitors. G1/S checkpoint in p53-mutant cells is absent, and therefore, cells in this case rely on the G2/M ATR-CHK1 checkpoint to survive after DNA damage[10][11].



6.2 ATR Inhibitors and DNA Replication Checkpoint Control

One of the most important synthetic lethal approaches in p53-mutant tumors is ATR (ataxia telangiectasia and Rad3-related) kinase inhibitors. G1/S checkpoint in p53-mutant cells is absent, and therefore, cells in this case rely on the G2/M ATR-CHK1 checkpoint to survive after DNA damage[10][11].

6.3 PARP Inhibitors in Homologous Recombination-Deficient p53-Mutant Tumors

Phase II trials of ATR inhibitor M6620 with gemcitabine in PTEN-deficient or p53-mutant cancers showed an improvement of progression-free survival (22.9 weeks) in combination with gemcitabine (14.7 weeks) monotherapy[10][11].

6.4 CHK1 Inhibitors and G2 Checkpoint Abrogation

Inhibitors of CHK1 directly interfere with G2/M checkpoint regulation in comparison to ATR inhibitors, causing mitotic catastrophe in cells with mutated p53[10][11].

7. Epigenetic and Transcriptional Modulation Strategies

7.1 DNA Methyltransferase Inhibitors and p53 Reactivation

CpG methylation patterns of p53 and related genes change in response to DNA methyltransferase inhibitors (azacitidine, decitabine) and alterations in CpG methylation status[2][10][11]. Decitabine and arsenic trioxide Phase I/II trials of TP53-mutant AML or MDS patients have demonstrated a reduction in tumor burden[2][10][11].

7.2 Histone Deacetylase Inhibitors

Inhibitors of histone deacetylase (HDAC) enhance p53 acetylation to stabilize and activate p53 transcription[10][11].

8. Clinical Trial Landscape and Regulatory Considerations

8.1 Current Clinical Trials and Development Stage

There are several p53-targeted therapeutics undergoing active clinical trials[2][10][11]: Approved Therapeutics: Gendicine (rAd-p53): Chinese regulatory authorities approved Gendicine (rAd-p53) in the treatment of head and neck squamous cell carcinoma. Late-Stage development (Phase II/III): Multiple Phase II/III trials in melanoma, esophageal, ovarian cancer, Multiple MDM2 trials Multiple ATR trials Multiple Phase II/III trials in p53-mutant tumors APR-246 (eprenetapopt): Multiple phase II/III trials in melanoma, esophageal, ovarian cancer, Multiple MDM2 trials Multiple ATR trials Multiple Phase II/III trials in p53-mutant tumors Phase I/II Phase I/II trials across a variety of cancer types COTI-2: Phase I/II trials, PROTAC based degraders of MDM2 Phase I trials, Novel p53 reactivator Phase I trials.

8.2 Biomarker Requirements and Patient Selection

The p53-directed therapy should be most effectively implemented in the clinic with the help of Comprehensive TP53 Mutation Analysis NGS that will help identify particular mutations and distinguish between the types of mutations. Functional Assessment To identify cases of selected cases, functional assays that can be used to define p53-reactivation response. Parallel Molecular Profiling Determination of MDM2 status, expression of p53-binding protein, expression of calcium channel. Immune Profiling Tumor mutational burden, immune inflammation, cGAS-STING pathway.

8.3 Regulatory and Reimbursement Considerations

Gendicine is the only approved cancer gene therapy regulatory drug, which is active today. Extensive implementation has a number of obstacles, Companion Diagnostic Requirements Regulatory agencies demand validated companion diagnostics,

Complex Clinical Trials Mutation-specific efficacy will need large patient numbers or enrichment strategies, Reimbursement Framework Health systems need to acknowledge treatment value.

9. Case Presentations: Mutation-Specific Treatment Approaches

9.1 Case 1: High-Grade Serous Ovarian Cancer with R175H Mutation

Clinical Scenario, A 52-year-old female with recurrent platinum resistant HGSOC. p53 R175H mutation is identified by genomic profiling. Treatment Regimen, Think about APR-246 or COTI-2 monotherapy, In case of limited reaction, rechallenge platinum, In the event of immunotherapy markers are positive, put on the use of anti-PD-1 pharmaceutical. Biology R175H mutations are sensitive to p53-reactivating compounds via partial restoration of wild-type conformation[1][2][8][10].

9.2 Case 2: Triple-Negative Breast Cancer with Frameshift TP53 Mutation

Clinical Case a 45-year-old female patient who presented with a recent diagnosis of TNBC and has been diagnosed with frame-shift TP53 mutation and CACNA1D downregulation. Treatment, COTI-2 with neoadjuvant chemotherapy, Think about, SERCA inhibitor in conjunction to apoptosis, Reserve immunotherapy in remnant disease. Frameshift mutations of the rationale in the CACNA1D gene lead to downregulation of CACNA1D, which creates a susceptibility to SOCE restoration by COTI-2[5][7][11].

9.3 Case 3: Breast Cancer with R273H Mutation and High TMB

Clinical Scenario The patient is a 58-year-old male with metastatic breast cancer who possesses p53 R273H mutation with increased TMB and high PD-L1 expression. Treatment Approach Immune checkpoint inhibitor, Including ATR or PARP inhibitor. Combined immunotherapy chemotherapy: take into account in case of poor response. R273H mutations in rationale cause genomic instability-based cGAS-STING immune activation, which assumes better ICI sensitivity[9][10].

10. Challenges and Limitations of Current Approaches

10.1 Genetic and Epigenetic Complexity

Nonetheless, there are still unmet challenges Concurrent Genetic Alterations Most cancers have numerous mutations other than TP53 that have a very profound effect on p53-directed therapy outcomes. Clonal Heterogeneity Tumors often have numerous p53-mutant clones that have varying mutations. Epigenetic Silencing There is p53 epigenetic silencing in some p53-mutant tumors.

10.2 Mechanistic Heterogeneity and Functional Assays

Whereas functional heterogeneity of p53 mutations is being increasingly appreciated, it has not been applied clinically. Standardized Functional Assays There are no validated clinical assays that detect the sensitivity of p53 reactivators. The development of the computational models was done to predict the p53 reactivator response. Drug sensitivity Patient-derived xenografts or ex vivo tumor samples used in functional testing.

10.3 Resistance Mechanisms and Therapeutic Escape

One of such mechanisms is, Receptor-Mediated Endocytosis Downregulation. Pathway Bypass Alternative Bypass apoptosis mediated by p53. p53-Independent Survival Development of p53 independent mechanisms.

10.4 Clinical Trial Design and Patient Accrual

Mutation-specific trials have distinctive issues Small Populations: It is challenging to find enough patients to have a conventional trial. Enrichment Strategies Can speed up the trials but restrict the generalizability. Combination Complexity Best combinations involve designs that are factorial.

11. Future Directions: Emerging Therapeutic Modalities

11.1 mRNA Nanomedicine and Gene Replacement Therapy

The development of the mRNA technology and the delivery system of lipid nanoparticles have facilitated the systemic delivery of wild-type p53 mRNA[11][12].

11.2 RNA-Based Therapeutics and Therapeutic Combinations

RNA interference and microRNA-based drugs provide a new level of flexibility in targeting the p53-related pathways[10][11][12].

11.3 Tumor-Infiltrating Lymphocyte Therapy

TIL therapy as used with p53-reactivating compounds or gene therapy is a new form of immunotherapy[2][10][11].



11.4 Combination Polytherapy Strategies

Rational multi-drug regimens aiming at a variety of p53-related weaknesses are p53 reactivator & MDM2 inhibitor p53 reactivator and immunotherapy. p53 reactivator and calcium-channel modulators. p53 reactivator and DNA replication inhibitors. p53 reactivator and traditional chemotherapy.

12. Future Perspectives

The finding of significant functional heterogeneity of p53 mutations is a paradigm change in the biology of cancer. Instead of considering all p53 mutations to be deleterious everywhere, it is emerging that mutation-specific oncogenic pathways, prognostic, and therapeutic debilitating effects are real.

Key Evidence Supporting p53-Directed Therapy

Hotspots (R175H, R248W, R273H) have different molecular pathogenesis and oncogenesis[1][8]. Type-specific therapeutic sensitivities of mutation have been discovered[8][9]. There are also specific molecular weaknesses with respect to the type of mutation[9]. Make a combination therapy with many vulnerabilities is more effective[5][11]. Even functional heterogeneity in the same residue requires special methods[8].

Clinical Implementation Pathway

Precision p53-directed oncology realization will need coordinated progress. Molecular Profiling full genomic characterization which includes the TP53 mutation type. Computational Prediction Model Development Standardized functional assays and computational prediction models. mutation-enriched clinical trials Biomarker-Driven Trial Design. Regulatory Framework well-defined regulatory mechanisms on companion diagnostics. Clinical Integration into normal oncology practice.

Future Therapeutic Innovations

New opportunities include Improved Systems of Gene Therapy delivery into systemic wild-type p53 delivery, Combinations Drugs Rational Multidrug Combinations: Using advanced systems, Multiple Vulnerabilities can be addressed with a combination of drugs, Immunotherapy Integration: Multiple mutation-specific immune activation uses, Calcium-Signaling Modulation: Clinical Translation Multiple mutation-specific Frameshift and Stop mutations use Cellular systems: Multiple Vulnerabilities can be targeted using a combination of drugs, Synthetic Lethality.



Conclusion:

TP53 mutations are an opportunity and a challenge of cancer medicine. Instead of considering TP53 mutations as being a universally lethal molecular occurrence, some new evidence shows that certain mutations offer viable points of weakness that can be exploited by therapeutic targeting. Combined with whole-genome profiling, functional studies, and mutation-directed treatment choice, the approach will enhance precision oncology and enhance the outcomes of the large percentage of cancer patients with mutations in p53-related malignancies. The shift to customized treatment of mutation-specific cancers carrying p53-mutations is a paradigm shift with far-reaching consequences as far as further precision medicine in the oncology field is concerned.

References:

[1] Chen, T., Ashwood, L. M., Kondrashova, O., Strasser, A., Kelly, G., & Sutherland, K. D. (2024). Breathing new insights into the role of mutant p53 in lung cancer. *Oncogene*, 44, 115–129. https://doi.org/10.1038/s41388-024-03219-6

[2] Qi, L., Li, G., Li, P., Wang, H., Fang, X., He, T., & Li, J. (2024). Twenty years of Gendicine—rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of oncology. *Genes & Diseases*, 11, 101155. https://doi.org/10.1016/j.gendis.2023.101155

[3] Rabab, K. E., Buchanan, P. J., Colley, G., White, A., Murphy, A., McCormack, C., & Eustace, A. J. (2025). TP53 Mutation-Specific Dysregulation of Store-Operated Calcium Entry and Apoptotic Sensitivity in Triple-Negative Breast Cancer. *Cancers*, 17(10), 1614. https://doi.org/10.3390/cancers17101614

[4] Andrysik, Z. (2025). Harnessing p53 for targeted cancer therapy. *Drug Discovery Today*, 30(1), 103906. https://doi.org/10.1080/21541264.2025.2452711

[5] Taritsa, I. C. (2025). Current cancer therapeutics targeting mutant p53. *Frontiers in Pharmacology*, 16, 1529483. https://doi.org/10.3389/fphar.2025.1529483

[6] Timofeev, O. (2021). Editorial: Mutant p53 in Cancer Progression and Treatment. *Frontiers in Oncology*, 11, 635410. https://doi.org/10.3389/fonc.2021.635410

[7] Kamath, D. (2024). Therapeutic potential of combating cancer by restoring wild-type p53 through advances in mRNA nanomedicine. *Nature Reviews Cancer*, 24(2), 89–106.

[8] Lin, W.-C., Liu, K., Wilhelms Garan, L. A., & Lin, F.-T. (2025). p53 mutant R273H opens new avenues for future cancer treatment. *Communications Biology*, 8(11), 1325. https://doi.org/10.1038/s44319-025-00352-5

[9] Inside Precision Medicine. (2025, November 4). How a p53 Mutation Can Sensitize Tumors to Immunotherapy. Retrieved from https://www.insideprecisionmedicine.com/topics/oncology/how-a-p53-mutation-can-sensitize-tumors-to-immunotherapy/

[10] The Development of p53-Targeted Therapies for Human Cancers. (2023). *Nature Reviews Drug Discovery*, 22(7), 529–551. https://doi.org/10.1038/s41573-023-00769-4

[11] Funk, J. O., & Wahl, M. (2017). Molecularly targeted therapies for p53-mutant cancers. *Journal of Clinical Medicine*, 6(8), 83. https://doi.org/10.3390/jcm6080083

[12] Distinct functional heterogeneity of TP53 R175 mutations in platinum-resistant recurrent ovarian cancer. (2025). *Cell Death & Disease*, 16(11), 789. https://doi.org/10.1038/s41419-025-08172-0

[13] Clinical Trials.gov. (2024). Safety and Efficacy of p53 Gene Therapy Combined with Chemotherapy. NCT03544723. Retrieved from https://clinicaltrials.gov/study/NCT03544723